Malvern, PA - YPrime announces the release of its data-driven electronic clinical outcome assessment (eCOA) technology platform. Designed to capture endpoints from multiple modalities and streamline patient data collection in clinical trials, YPrime's eCOA technology supports sponsors, sites and patients while delivering consumer-friendly applications built on the best standards of user experience principles.
YPrime's eCOA solutions offer data capture in virtually any clinical research setting, with features that promote user convenience, compliance and data integrity:
"YPrime's approach to eCOA is a great example of our collective efforts to uncomplicate patient data collection," said Shawn Blackburn, CEO and co-founder. "This platform, which offers the most advanced features in the marketplace, provides the tools that make clinical endpoint collection quicker, easier and considerably less frustrating. Technology that focuses on the end user's experience, particularly for site and patients will have a landmark effect on the way we conduct clinical trials in the future."
About YPrime
YPrime offers more than a decade of focused work with eclinical systems to expedite and improve the quality of patient management, clinical supplies, drug accountability and clinical data. Cloud-based interactive response technology (IRT) and electronic clinical outcome assessment (eCOA) platforms enable greater speed, precision and integration in clinical trial management. Our data services tools help sponsors bring together fragmented clinical research data into contextual information they can act on. YPrime's technology and service offerings enable sponsors to move faster and more efficiently to their next development milestone.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.